SenzaGen receives GLP approval

SenzaGen, which develops animal-free in vitro safety tests, has received the important GLP approval from Swedac for its laboratory and the use of its test platform GARD™. The internal work began in 2019 and today, May 27, the Company received the GLP approval. This is a substantial regulatory milestone since the GLP status gives SenzaGen…

Read more

SenzaGen receives SEK 0.5 million order from world-leading ingredient and raw material supplier

SenzaGen will assess the skin sensitizing hazards of chemicals for a global company specialized in ingredients and raw materials for several different industries and markets. The new order, with a value of approximately SEK 0.5 million, includes testing with both GARD™skin and GARD™potency. The unique ability of the GARD technology to both assess “difficult-to-test” chemicals…

Read more

SenzaGen and the Research Institute for Fragrance Materials (RIFM) collaborate to develop next-generation test for photosensitization

SenzaGen has entered into collaboration with the Research Institute for Fragrance Materials (RIFM). The collaboration means that SenzaGen, with the support of a RIFM grant, will test several substances for RIFM to assess whether some fragrance materials could cause skin allergies when exposed to sunlight, so-called photosensitization. The cooperation agreement runs through 2021.

Read more

SenzaGen and XCellR8 expand their collaboration to offer GARD[®]skin Animal Product-Free

SenzaGen, a Swedish developer of animal-free in vitro tests for sensitization and the British contract testing laboratory, XCellR8, have deepened and expanded their collaboration by signing an exclusive global licensing agreement. The new agreement covers the performance, marketing and sales of SenzaGen's new, vegan skin sensitization test, GARD[®]skin Animal Product-Free.

Read more

SenzaGen: Invitation to full year 2019 conference call on Feb 13 at 9.30 CET

SenzaGen is pleased to invite press and investors to a conference call on Thursday February 13 at 9.30 CET where CEO Axel Sjöblad comments SenzaGen’s 2019 full year results.

Read more

SenzaGen receives order of SEK 0.6 million from new global customer

SenzaGen will assess the sensitizing hazards of chemicals for a new global customer with in-house product development. The assignment includes SenzaGen's tests to assess whether chemical substances can cause allergic reactions in skin (GARD[™]skin) or in the respiratory tract (GARD[™]air) with a value of approximately SEK 0.6 million. The tests will be carried out at…

Read more

SenzaGen signs distribution agreement with GenEvolutioN in France

SenzaGen has signed a three-year distribution agreement with the French contract research laboratory GenEvolutioN. With this agreement SenzaGen further broadens its licensing and distribution network in Europe with another strategically important partner for toxicological in vitro studies. 

Read more

SenzaGen signs distributor agreement with VitroScreen in Italy

SenzaGen has signed a distribution agreement with the VitroScreen Laboratory based in Milan, Italy. With the agreement, which initially runs for a period of three years, SenzaGen expands its licensing and distribution network with an innovative and established partner for in vitro Toxicology in Europe, one of SenzaGen's focus markets.

Read more

SenzaGen presents a new commercial organization and a new financial target

The evolution of SenzaGen in recent years has seen the company change from a research organization to one with a strong focus on commercialization. Recently, a new CEO was appointed, and the company now announces a brand new commercial organizational structure with increased focus on marketing and sales.

Read more

SenzaGen expands its product portfolio with a test for the Medical Devices market

SenzaGen today announced an expansion of its product portfolio with the launch of GARD™skin Medical Device – a new test to assess whether medical devices can cause skin allergies. Regulatory changes are already underway in the market, which will mean increased requirements for product safety. Together with the ongoing trend towards reducing animal testing in…

Read more

SenzaGen granted its first patent for GARD™potency

SenzaGen's patent application that protects the biomarker signature to measure how strongly allergenic a substance is, has now been granted in Europe. The patent is SenzaGen's first patent in the area of potency classification. The patent's validity extends to 2036.

Read more

SenzaGen receives new order of SEK 0.5 m from a recurring customer

SenzaGen has received an order for the allergy test platform GARD® valued at approximately SEK 0.5 million. The order is from a recurring customer with its own product development facility. Deliveries are planned to take place gradually during 2019.

Read more

EU highlights SenzaGen's animal-free test – the world's first of its kind to assess whether chemical substances can cause respiratory allergies

Today, International Asthma Day is being recognized worldwide. Asthma is a global health problem - over 300 million have a diagnosis and nearly 1 million Swedes are affected – a number expected to increase. The EU has invested in the development of the world's first in-vitro test for respiratory sensitization. GARD®air was developed by the…

Read more

SenzaGen appoints Axel Sjöblad as new CEO – mission to lead the company into an expansive sales phase

Over the last few years SenzaGen has made major progress, bringing the company to the next phase with increased focus on marketing and sales. In accordance with the company's strategic plan and accelerating commercial activities, SenzaGen's Board has appointed Axel Sjöblad as new CEO starting June 17, 2019. Axel most recently held the position as…

Read more

SenzaGen increases its presence in the US via a license agreement with MB Research Labs

SenzaGen has signed a license agreement with the contract research organization (CRO), MB Research Labs, which is a leader in GLP in vitro toxicological testing in the United States. The agreement gives MB Research Labs the right to market and sell SenzaGen’s animal-free GARD™ test platform worldwide and also further strengthening SenzaGen’s presence in the…

Read more

SenzaGen granted additional patent in Asia

SenzaGen today announced that the South Korean Patent Office (KIPO) has approved SenzaGen's patent application for GARD™skin. The new patent gives SenzaGen a strong intellectual property position in several strategically important markets.

Read more

SenzaGen takes a first step into China – cooperates with leading expert

SenzaGen (Nasdaq First North: SENZA) has initiated a partnership with Guangzhou Chn-Alternative Biotechnology Co., Ltd (CHNALT), a leading provider of alternative, animal-free testing methods in China. The new collaboration aims to establish local networks and ensure SenzaGen with its GARD™ genome-based testing method has a strong position as China moves towards introduction of animal-free chemical…

Read more

SenzaGen strengthens its organization with IR and communications director

Lund, December 5, 2018 - SenzaGen (Nasdaq First North: SENZA) today announced that the company has recruited Tina Dackemark Lawesson as communications director. Dackemark Lawesson joins SenzaGen with a wealth of experience from IR and communications positions in similar life science companies and takes up her position in December 2018.

Read more

Senzagen strengthens US organisation and commercial presence with aim to enroll more licensees

Lund, October 11, 2018 - SenzaGen (Nasdaq First North: SENZA) today announces that the Company is strengthening its presence in the important US market through a major strategic recruitment. The recruitment of Dr. Joshua J. Schmidt as Business Development Director at SenzaGen Inc represents a further expansion of the Company's commercial organization and an increasing…

Read more

Senzagen presents financial targets

Lund, October 9, 2018 – The SenzaGen Board of Directors (Nasdaq First North: SENZA) announces today that it has adopted financial targets. The underlying reasons behind this decision are the successful development in-house of a broad and unique product portfolio, the growing number of partnerships being established with CROs and other industrial partners, and the…

Read more

ECVAM evaluation of GARDskin rescheduled to an extra scientific committee meeting in spring 2019

Lund, September 18, 2018 - SenzaGen (Nasdaq First North: SENZA) has been notified by the European Center for the Validation of Alternative Methods (ECVAM) authority that due to time constrains their scientific committee (ESAC) will not be able to evaluate tests in the category ”Test Guidelines on Health Effects”, to which GARDskin belongs, this year.…

Read more

SenzaGen launches the first in vitro airway allergy test – GARDair – at ESTIV2018

Lund, September 18, 2018 - SenzaGen (Nasdaq First North: SENZA) announced today that the company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and opening a completely new market, GARDair is based on the company’s proprietary…

Read more

SenzaGen targets the growing medical device market

Lund, August 29, 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the Company is now expanding its market focus to the medical device market. This market is in strong growth as a result of a growing and aging population in combination with a new regulatory framework for medical devices and increased quality standards.

Read more

Notice of extraordinary General meeting of SenzaGen AB

The shareholders of SenzaGen AB, reg. no. 556821-9207, (the “Company”) are hereby summoned to the extraordinary general meeting on Friday 7 September 2018 at 08.00 at Medicon Village, building 401 Länken 2, Scheelevägen 2 in Lund.

Read more

Scientific study shows that GARDskin™ is the most accurate test for skin sensitization of chemical substances

Lund, 31 July 2018 – SenzaGen (Nasdaq First North: SENZA) announces today that a new scientific study shows that GARDskin™ can provide producers and contract laboratories with a single test for evaluating substances, with an increased accuracy as compared with the recommended combination of current market leading methods. The reason for this recommendation by regulatory…

Read more

SenzaGen signs distribution agreement with the French test laboratory Eurosafe

Lund, July 16, 2018. SenzaGen (Nasdaq First North: SENZA) and the French CRO Eurosafe announce today that they have entered into a distribution agreement regarding GARDskin™ and GARDpotency™.  The GARD™ portfolio consists of animal-free tests developed by SenzaGen for safety assessment of chemical ingredients and mixtures. The agreement confirms the interest in SenzaGen’s technology and…

Read more

SenzaGen receives patent protection for GARDskin™ in China

Lund, July 11th 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the Chinese Patent Office (CPO) has granted a patent for GARDskin™, the company's test that analyses the risk that chemical substances will induce skin allergies. The tests in the GARD™ portfolio outperform all currently available traditional validated methods, while at the same…

Read more

SenzaGen's final validation report for the animal-free allergy test GARDpotency™ has been submitted to the regulatory authorities

Lund, July 9, 2018. SenzaGen (Nasdaq First North: SENZA) announces today that the company has submitted the official validation report for GARDpotency™ to the relevant regulatory authorities as a complement to the validation of GARDskin™. GARDpotency™ is the first animal-free allergy test on the market that can be used to evaluate chemicals according to the…

Read more

SenzaGen signs key license agreement in the US with Burleson Research Technologies

Lund, March 7, 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the company has signed a strategically important license agreement with the well renowned Burleson Research Technologies Inc. (BRT). BRT will market and provide GARD™ in the US and perform the test in its laboratory in North Carolina. BRT is the first US…

Read more

SenzaGen appoints new Chief Scientific Officer

Lund, March 7, 2018 - SenzaGen (Nasdaq First North: SENZA) today announced that the company has recruited Dr Gunilla Grundström as its new Chief Scientific Officer. She has more than 10 years of commercial experience in the pharmaceutical and medical technology industry and comes most recently from a position as Senior Research Manager at Baxter. 

Read more

SenzaGen signs its first global licensing agreement with Eurofins BioPharma Product Testing Munich

Lund, 15 February, 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the company has signed a global licensing agreement with the leading contract research organization Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich), to market the GARD™ test to its clients. GARD™ is a genome-based test, with higher accuracy than other available test…

Read more

SenzaGen’s final validation report of GARDskin™ submitted to regulatory authorities – reveals highest test prediction accuracy in the field

Lund, January 12, 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the company has submitted the final report for the validation of GARDskin™ to the regulatory authorities. Global regulatory approval and recommendation by ECVAM and OECD on the use of GARDskin is expected in April 2019. The final result presented in the report…

Read more

SenzaGen reports positive results from ring trial in the validation of GARDskin™

Lund, 14th December 2017 - SenzaGen (Nasdaq First North: SENZA) today reports highly positive results from the final laboratory stage in the validation of GARDskin™. The results form an important part of the evidence in the approval process for the validation by ECVAM and OECD International Regulatory Authorities. In the recently completed evaluation, GARDskin continues…

Read more

GARDprotein demonstrates exceptional ability to identify allergens in foodstuff – new research results presented at scientific conference.

Lund, 10th October 2017 – SenzaGen (Nasdaq First North: SENZA) today announces positive results from an evaluation of GARDprotein, a test method which is developed to make it possible to eliminate allergenic proteins from today's and tomorrow's foodstuffs. GARDprotein has the potential to open up a new market for SenzaGen's test platform. The results are…

Read more

SenzaGen to present at EUROTOX Congress in Slovakia

SenzaGen announces today that the company will be presenting two scientific abstracts and hold a presentation titled "21st century testing: Can one test be stand alone?" at the upcoming EUROTOX Congress in Bratislava, Slovakia.

Read more

SenzaGen's chairman Carl Borrebaeck has received the Biotech Builders Award 2017

SenzaGen's chairman, Professor Carl Borrebaeck, has received the prestigious BiotechBuilders Award for his ground-breaking medical research and prominent role as entrepreneur in Life Science, including being the co-founder of SenzaGen, Immunovia, Alligator Bioscience and BioInvent. The award was announced at the annual BiotechBuilder's meeting in Stockholm on 28 August. Through his involvement in SenzaGen, Carl…

Read more

SenzaGen secures patent protection for its GARDskin™ test in Europe

SenzaGen announces today that the European Patent Office (EPO) has granted a patent for GARDskin™, the company's recently launched test that determines whether chemical substances may induce skin allergies. GARD™ tests are significantly more reliable than traditional evaluation methods, and provide more comprehensive information on the allergy-inducing properties of the chemicals studied. Hence, GARD™ confers…

Read more

SenzaGen recruits Chief Commercial Officer and Chief Scientific Officer

SenzaGen announces today that the company has recruited Anna Chérouvrier Hansson as Chief Commercial Officer and Dr. Henrik Appelgren as Chief Scientific Officer. The company's management is thus strengthened in the run-up to the commercialization of the company's GARD tests, which are used to assess the allergenic properties of chemical substances.

Read more

SenzaGen signs global distribution agreement with Charles River Laboratories

SenzaGen announces today that the company has signed a global distribution agreement with Charles River Laboratories, a leading early-stage contract research organization, to market GARDskin to their clients globally. GARDskin has the potential to replace traditional methods in regulatory testing, in accordance with European REACH Regulation.

Read more

Positive research results for SenzaGen's GARDpotency test published in leading scientific journal

SenzaGen announces today that a scientific evaluation of GARDpotency shows that the test reveals with high accuracy whether chemical substances are allergenic and how strong the allergic effect of the chemical is. The results have been published in the prestigious scientific journal Altex. GARDpotency is a gene-based test which is carried out in vitro, thus eliminating…

Read more

SenzaGen and AstraZeneca initiate technology development collaboration

SenzaGen has signed a collaboration agreement with the global biopharmaceutical  company AstraZeneca. The collaboration focuses on  testing and development of SenzaGen's sensitization test GARDair, in order to distinguish between allergens and irritants in the respiratory tract. The goal is the validation of in vitro toxicological tests that could be applied to the discovery of new…

Read more

SenzaGen introduces GARDpotency - a unique method for measuring the allergenicity of chemical substances

SenzaGen AB announces today the start of pilot sales of GARDpotency, the first animal-free method of analysis that can provide invaluable information on the allergenic potency of a chemical substance. GARDpotency is a unique complement to the previously launched test method GARDskin.

Read more

SenzaGen awarded EU grant of € 2,4 million in heavy competition, to develop GARDair for industry use

SenzaGen has received a grant of € 2,4 million from the EU's research and innovation framework program Horizon 2020 to develop GARDair, the first generation test for respiratory allergies.

Read more

SenzaGen and Bioglan working together for the next generation of test methods

SenzaGen has signed a cooperation agreement with the pharmaceutical company Bioglan, which develops and manufactures creams and ointments for the pharmaceutical and cosmetics industries. The collaboration means that Bioglan will test GARDskin for skin allergens in a number of creams that are included in various end products.

Read more

SenzaGen signs distribution agreement in Korea

SenzaGen has signed a distribution agreement with the Korean company WOOJUNG BSC, Inc.  Korea passed a legislation to ban animal testing of cosmetics on December 2015, which will be effective on February 4, 2017. With this new agreement, SenzaGen will enter one of the world's most exciting markets and WOOJUNG BSC will market GARDskin for…

Read more

SenzaGen invited to prestigious meeting at ICCVAM, US

On Tuesday the 27 September SenzaGen is invited to participate at a science Committee Meeting of the American organization ICCVAM *, which promotes the development of alternative methods to replace animal testing. Together with its US partner, Burleson Research Technologies, Inc., SenzaGen will participate in the official program and make a statement about Skin Sensitization…

Read more

SenzaGen signs its first distribution agreement with British XCellR8, a leader in animal-free testing

In line with SenzaGen’s long-term strategy and business model, the company has now signed its first distribution agreement with the British test lab company XCellR8. The agreement confirms the interest in SenzaGen’s technology and opens up new business opportunities as XCellR8 will actively market the GARDskin for cosmetics, personal care and household products and their…

Read more

SenzaGen Invited to High-Tech Health Research Expo in Washington, D.C.

SenzaGen have been invited by U.S. Representative Tom Marino to present the company's technology at the High-Tech Health Research Expo in Washington, D.C., where SenzaGen will meet US congressmen and federal procurement officials interested in the use of high-tech human-focused methods to replace animal tests. The Expo takes place on September 15th, 2016.

Read more

SenzaGen initiates cooperation with partners in Europe and the US

The final and most important step in SenzaGen's formal validation process of the sensitization test GARD has now commenced through partnerships with two external laboratories, Eurofins (Germany) and Burleson (USA). These partners will now verify GARD's reliability and reproducibility, which will allow the test to be carried out by external contract laboratories.

Read more

SenzaGen wins DI’s Gasellsprånget – most promising company to become Supergasell within 5 years

On May 25, SenzaGen was elected winner at the Swedish newspaper Dagens Industri’s event and competition Gasellsprånget, at the national finale in Gothenburg. After a tough round of questions and an audience poll, SenzaGen was elected winner with the greatest market potential and future outlook, leaving the competitor DigiExam a close second.

Read more

SenzaGen presents a new commercial organization and a new financial target

The evolution of SenzaGen in recent years has seen the company change from a research organization to one with a strong focus on commercialization. Recently, a new CEO was appointed, and the company now announces a brand new commercial organizational structure with increased focus on marketing and sales.

Read more

SenzaGen receives new order of SEK 0.5 m from a recurring customer

SenzaGen has received an order for the allergy test platform GARD® valued at approximately SEK 0.5 million. The order is from a recurring customer with its own product development facility. Deliveries are planned to take place gradually during 2019.

Read more

Notice of Annual General Meeting of SenzaGen AB (publ)

The shareholders in SenzaGen AB (Publ.), Org. nr 556821–9207, ("Company") is hereby summoned to the Annual General Meeting held on Wednesday of the 15 May 2019 at 16.00 in Arrhenius at Medicon Village, building 401, Scheelevägen 2 in Lund.

Read more

SenzaGen appoints Axel Sjöblad as new CEO – mission to lead the company into an expansive sales phase

Over the last few years SenzaGen has made major progress, bringing the company to the next phase with increased focus on marketing and sales. In accordance with the company's strategic plan and accelerating commercial activities, SenzaGen's Board has appointed Axel Sjöblad as new CEO starting June 17, 2019. Axel most recently held the position as…

Read more

SenzaGen increases its presence in the US via a license agreement with MB Research Labs

SenzaGen has signed a license agreement with the contract research organization (CRO), MB Research Labs, which is a leader in GLP in vitro toxicological testing in the United States. The agreement gives MB Research Labs the right to market and sell SenzaGen’s animal-free GARD™ test platform worldwide and also further strengthening SenzaGen’s presence in the…

Read more

SenzaGen granted additional patent in Asia

SenzaGen today announced that the South Korean Patent Office (KIPO) has approved SenzaGen's patent application for GARD™skin. The new patent gives SenzaGen a strong intellectual property position in several strategically important markets.

Read more

SenzaGen strengthens its organization with IR and communications director

Lund, December 5, 2018 - SenzaGen (Nasdaq First North: SENZA) today announced that the company has recruited Tina Dackemark Lawesson as communications director. Dackemark Lawesson joins SenzaGen with a wealth of experience from IR and communications positions in similar life science companies and takes up her position in December 2018.

Read more

Senzagen strengthens US organisation and commercial presence with aim to enroll more licensees

Lund, October 11, 2018 - SenzaGen (Nasdaq First North: SENZA) today announces that the Company is strengthening its presence in the important US market through a major strategic recruitment. The recruitment of Dr. Joshua J. Schmidt as Business Development Director at SenzaGen Inc represents a further expansion of the Company's commercial organization and an increasing…

Read more

Senzagen presents financial targets

Lund, October 9, 2018 – The SenzaGen Board of Directors (Nasdaq First North: SENZA) announces today that it has adopted financial targets. The underlying reasons behind this decision are the successful development in-house of a broad and unique product portfolio, the growing number of partnerships being established with CROs and other industrial partners, and the…

Read more

ECVAM evaluation of GARDskin rescheduled to an extra scientific committee meeting in spring 2019

Lund, September 18, 2018 - SenzaGen (Nasdaq First North: SENZA) has been notified by the European Center for the Validation of Alternative Methods (ECVAM) authority that due to time constrains their scientific committee (ESAC) will not be able to evaluate tests in the category ”Test Guidelines on Health Effects”, to which GARDskin belongs, this year.…

Read more

SenzaGen launches the first in vitro airway allergy test – GARDair – at ESTIV2018

Lund, September 18, 2018 - SenzaGen (Nasdaq First North: SENZA) announced today that the company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and opening a completely new market, GARDair is based on the company’s proprietary…

Read more

SenzaGen targets the growing medical device market

Lund, August 29, 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the Company is now expanding its market focus to the medical device market. This market is in strong growth as a result of a growing and aging population in combination with a new regulatory framework for medical devices and increased quality standards.

Read more

Notice of extraordinary General meeting of SenzaGen AB

The shareholders of SenzaGen AB, reg. no. 556821-9207, (the “Company”) are hereby summoned to the extraordinary general meeting on Friday 7 September 2018 at 08.00 at Medicon Village, building 401 Länken 2, Scheelevägen 2 in Lund.

Read more

Scientific study shows that GARDskin™ is the most accurate test for skin sensitization of chemical substances

Lund, 31 July 2018 – SenzaGen (Nasdaq First North: SENZA) announces today that a new scientific study shows that GARDskin™ can provide producers and contract laboratories with a single test for evaluating substances, with an increased accuracy as compared with the recommended combination of current market leading methods. The reason for this recommendation by regulatory…

Read more

SenzaGen signs distribution agreement with the French test laboratory Eurosafe

Lund, July 16, 2018. SenzaGen (Nasdaq First North: SENZA) and the French CRO Eurosafe announce today that they have entered into a distribution agreement regarding GARDskin™ and GARDpotency™.  The GARD™ portfolio consists of animal-free tests developed by SenzaGen for safety assessment of chemical ingredients and mixtures. The agreement confirms the interest in SenzaGen’s technology and…

Read more

SenzaGen receives patent protection for GARDskin™ in China

Lund, July 11th 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the Chinese Patent Office (CPO) has granted a patent for GARDskin™, the company's test that analyses the risk that chemical substances will induce skin allergies. The tests in the GARD™ portfolio outperform all currently available traditional validated methods, while at the same…

Read more

SenzaGen's final validation report for the animal-free allergy test GARDpotency™ has been submitted to the regulatory authorities

Lund, July 9, 2018. SenzaGen (Nasdaq First North: SENZA) announces today that the company has submitted the official validation report for GARDpotency™ to the relevant regulatory authorities as a complement to the validation of GARDskin™. GARDpotency™ is the first animal-free allergy test on the market that can be used to evaluate chemicals according to the…

Read more

SenzaGen signs key license agreement in the US with Burleson Research Technologies

Lund, March 7, 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the company has signed a strategically important license agreement with the well renowned Burleson Research Technologies Inc. (BRT). BRT will market and provide GARD™ in the US and perform the test in its laboratory in North Carolina. BRT is the first US…

Read more

SenzaGen appoints new Chief Scientific Officer

Lund, March 7, 2018 - SenzaGen (Nasdaq First North: SENZA) today announced that the company has recruited Dr Gunilla Grundström as its new Chief Scientific Officer. She has more than 10 years of commercial experience in the pharmaceutical and medical technology industry and comes most recently from a position as Senior Research Manager at Baxter. 

Read more

SenzaGen signs its first global licensing agreement with Eurofins BioPharma Product Testing Munich

Lund, 15 February, 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the company has signed a global licensing agreement with the leading contract research organization Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich), to market the GARD™ test to its clients. GARD™ is a genome-based test, with higher accuracy than other available test…

Read more

SenzaGen’s final validation report of GARDskin™ submitted to regulatory authorities – reveals highest test prediction accuracy in the field

Lund, January 12, 2018 - SenzaGen (Nasdaq First North: SENZA) announces today that the company has submitted the final report for the validation of GARDskin™ to the regulatory authorities. Global regulatory approval and recommendation by ECVAM and OECD on the use of GARDskin is expected in April 2019. The final result presented in the report…

Read more

SenzaGen reports positive results from ring trial in the validation of GARDskin™

Lund, 14th December 2017 - SenzaGen (Nasdaq First North: SENZA) today reports highly positive results from the final laboratory stage in the validation of GARDskin™. The results form an important part of the evidence in the approval process for the validation by ECVAM and OECD International Regulatory Authorities. In the recently completed evaluation, GARDskin continues…

Read more

GARDprotein demonstrates exceptional ability to identify allergens in foodstuff – new research results presented at scientific conference.

Lund, 10th October 2017 – SenzaGen (Nasdaq First North: SENZA) today announces positive results from an evaluation of GARDprotein, a test method which is developed to make it possible to eliminate allergenic proteins from today's and tomorrow's foodstuffs. GARDprotein has the potential to open up a new market for SenzaGen's test platform. The results are…

Read more

SenzaGen publicerar årsredovisningen för 2019

SenzaGens årsredovisning för 2019 är från och med idag tillgänglig på bolagets hemsida www.senzagen.com samt kan läsas via länken nedan.  

Read more

SenzaGens bokslutskommuniké 2019

Uppdaterad marknadsplan och ny försäljningsorganisation under uppbyggnad

Read more

SenzaGens halvårsrapport 2019

Framåt i linje med vår strategi

Read more

SenzaGen publicerar årsredovisningen för 2018

SenzaGen meddelar idag att årsredovisningen för 2018 finns tillgänglig på svenska. En digital version kan laddas ner på bolagets hemsida www.senzagen.com/investors/rapporter samt kan läsas via länken nedan. 

Read more

SenzaGens bokslutskommuniké 2018

Positiv utveckling för SenzaGen – intresset för GARD® fortsätter att öka

Read more

SenzaGens Delårsrapport 1 januari – 30 juni 2018

LUND, 22 augusti 2018 – SenzaGen (Nasdaq First North: SENZA) publicerar idag sin rapport för perioden 1 januari - 30 juni 2018

Read more

SenzaGens årsredovisning för 2017 är nu offentliggjord

SenzaGen AB:s årsredovisning för räkenskapsåret 2017 finns nu tillgänglig på svenska på bolagets hemsida, www.senzagen.com,  och på bolagets kontor med adress Medicon Village, Scheelevägen 2, 223 81 Lund. För mer information, kontakta: Anki Malmborg Hager, VD, SenzaGen AB Email: anki.malmborg.hager@senzagen.com Telefon:  0768 284822 Om GARD™ Genom att analysera hundratals markörer genererar GARD™ stora mängder data och levererar…

Read more

SenzaGens bokslutskommuniké 1 januari – 31 december 2017

Lund, 14 februari 2017 – SenzaGen (Nasdaq First North: SENZA) presenterar idag sin bokslutskommuniké för perioden 1 januari – 31 december 2017.

Read more

SenzaGen publicerar årsredovisning för räkenskapsåret 2016

SenzaGen AB:s årsredovisning för räkenskapsåret 2016 finns nu tillgänglig på bolagets hemsida (www.senzagen.com) och på bolagets kontor med adress Scheelevägen 2, Medicon Village i Lund. 

Read more

SenzaGen’s Annual Report 2017 has been published

The Annual Report 2017 of SenzaGen AB has been published and is available in Swedish at the company’s website www.senzagen.com.  Printed versions of SenzaGen’s Annual Report can be obtained at the company’s office at Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden. For more information, please contact: Anki Malmborg Hager, CEO, SenzaGen AB Email: anki.malmborg.hager@senzagen.com…

Read more